Arbutus Biopharma CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Arbutus Biopharma Corporation has announced its 2026 Annual General and Special Meeting of Shareholders will be held on May 26, 2026, to elect directors, approve an incentive plan, and vote on executive compensation.
NASDAQ
Arbutus Biopharma Corporation has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
Arbutus Biopharma will hold its 2025 Annual General Meeting of Shareholders virtually on May 21, 2025, to vote on director elections, executive compensation, and the appointment of an independent accounting firm.
NASDAQ
Arbutus Biopharma Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
NASDAQ
DEF 14A: Arbutus Biopharma Seeks Shareholder Approval for Director Elections and Incentive Plan Amendment
Arbutus Biopharma is holding its 2024 Annual General and Special Meeting of Shareholders on May 22, 2024, to vote on director elections, an amendment to the 2016 Omnibus Share and Incentive Plan, executive compensation, and the appointment of an independent registered public accounting firm.